Board of Directors

Lynnet Koh has extensive executive experience in leading major new technology and product innovations including new product design, development, and commercialization of multiple cutting-edge technologies within the telecom and biotecnology industries.  

​

​

John Leonard has more than 20 years of biopharma expereince focused on strategy, financing, and corporate dealmaking.  He has led multi-billion dollar licensing and M&A deals in Cell and Gene therapy at Thermo Fisher.  John has served in science and business leadership roles at  Eli Lilly, Genzyme, GSK, CASI Pharmaceuticals, HUYABIO International and CereGene.  

Dr. Paul Grint was most recently CEO and a member of the board of directors of AmpliPhi Biosciences which recently merged with C3J Therapeutics to form Armata Pharmaceuticals. Dr. Grint has more than two decades of experience in biologics  including the successful approval and commercialization of products infectious diseases, immunology and oncology.

David Kyle is a serial biotech entrepreneur with 40 years of expereince.  Dr. Kyle has founded multiple companies to exits including Martek Biosciences, Advanced BioNutrition, and Evolve BioSystems. (now Infinant Health)

​

​

​

Dr. Bissonnette is TargaZyme’s Head of oncology drug discovery and senior manager with more than 25-years-experience from discovery to commercialization.

​

​

​

​

Dr He is a Bioprocess Development and Manufacturing professional with extensive leadership experience in managing cross functional teams and leading multiple programs and projects simultaneously in Biopharmaceutical industry. Previously served as CTO at Legend Biotech and helped lead the company to an 8 billion dollar market cap.